Anatolijs Šaripo

 Born: February 5, 1962, Silene, Daugavpils, Latvia

Languages: Latvian, Russian, English

Scientific Interests

• Adenovirus Oncogenes, Adenovirus Expression vectors (Aivars Vilnis, MI, Latvia, 1983-1986)
• Baculovirus Sructural Proteins, Baculovirus Expression vectors (V.Solomko, MI, Kiev, Ukraine; G.Eglite, BI, Latvia, 1986-1992)
• Bacillus thuringiensis endotoxins (Dr. Rituma, Latvian Agricultural Academy, 1988-1994)
• Epstein-Barr virus antigens: presentation of virus epitopes for T-cell immune responce (Maria Masucci, MTC, KI, Sweden, 1994-2000)
• Ubiquitin-Proteasomal degradation of viral and cellular proteins (Maria Masucci, MTC, Magnus Ingelman-Sundberg, IMM, KI, Sweden, Pauls Pumpens, BMC, LU, Latvia, 1994-2003)
• Protein fnolding (Souren Mkrtchian, IMM, Sweden, Gottfried Otting, UA, Australia, Nicholas Dixon, UA, Australia, 1996-2003)
• Artificial Protein Design (Gottfried Otting, UA, Australia, Mats Persson, KI, Sweden, 1999-2003)
  
  

Education

• 1984  BSc, Faculty of Biology, University of Latvia, Riga, Latvia
• 1983-84 Biochemistry and molecular biology of proteins - training course at Russian Academy of Sciences, Pushchino, Russia
• 1991  PhD thesis, Institute of Viral Biopreparates, Moscow
• 1994  Nostrification (Dr.biol.) at Latvian  Academy of Sciences
• 1996  Protein Structure, Course by Professor C.-I. Branden at Karolinska Institute, Sweden

Professional Experience

• 1984-1993: Research assistant/Researcher, Kirchenstein Institute of Microbiology, Latvian Academy of Sciences
• 1993-2000: Head of Laboratory of Applied Microbiology , Kirchenstein Institute of Microbiology and Virology, Riga, Latvia
• 1994-2000: Guest researcher at MTC, Karolinska Institute, Sweden, (see home page at MTC, KI)
• 2000-2002: Guest researcher at IMM, Karolinska Institute, Sweden (see home page at IMM, KI)
• Since 2000: Principal Investigator, Group leader, Biomedicine Reaserch and Study Centre, University of Latvia, Riga, Latvia

Honours and Awards

•     Corresponding Member, Latvian Academy of Sciences, 2004

Professional Activities and Memberships

• Since 2002: Vice-Chairman of Scientific Council, Biomedicine Research and Study Centre, University of Latvia
• Since 2003: Member of Latvian Council of Science Expert Commission for Biotechnology, Microbiology, Molecular Biology and Virology
  

Students

• 1989 Ainars Leonchiks, Diploma Project at LU, Latvia
• 1994 Ginta Pece, Diploma Project at RTI, Latvia
• 1998 Olga Matvijenko, MSci Program at LU, Latvia
• 2000-2002 Ainars Leonchiks, PhD program, co-supervising at Karolinska Institute, Sweden
• 2001-present  Marina Koulikovska, PhD program, co-supervising at Linkopping University, Sweden
• 2002, Raitis Barbals, BSci Program at  LU, Latvia
• 2002, Karina Derkacha, BSci Program at  LU, Latvia
• 2003, Raitis Barbals, MSci Program at  LU, Latvia
• 2003, Karina Derkacha, MSci Program at  LU, Latvia

Representative Publications (PubMed referred, high impact factor only)    

• G.Pintacuda, A.Moshref, A.Leonchiks, A.Sharipo, G.Otting. Site-specific labelling with a metal chelator for protein-structure refinement. - J.Biomol. NMR, 2004, vol. 29, N 3, pp. 351-361.
• Liepinsh E, Barbals R, Dahl E, Sharipo A, Staub E, Otting G. The Death-domain Fold of the ASC PYRIN Domain, Presenting a Basis for PYRIN/PYRIN Recognition. - J. Mol. Biol. , 2003 Oct 3; 332 (5): 1155-63.
• Liepinsh E, Leonchiks A, Sharipo A, Guignard L, Otting G. Solution structure of the R3H domain from human Smubp-2. - J. Mol. Biol. , 2003 Feb 7; 326 (1): 217-23.
• Dantuma NP, Sharipo A, Masucci MG. Avoiding proteasomal processing: the case of EBNA1. - Curr. Top. Microbiol. Immunol., 2002; 269: 23-36. Review.
• Leonchiks A, Stavropoulou V, Sharipo A, Masucci MG. Inhibition of ubiquitin-dependent proteolysis by a synthetic glycine-alanine repeat peptide that mimics an inhibitory viral sequence. FEBS Lett. 2002 Jul 3;522(1-3):93-8.
• Sargsyan E, Baryshev M, Backlund M, Sharipo A, Mkrtchian S. Genomic organization and promoter characterization of the gene encoding a putative endoplasmic reticulum  chaperone, ERp29. Gene. 2002 Feb 20;285(1-2):127-39.
• Li L, Sharipo A, Chaves-Olarte E, Masucci MG, Levitsky V, Thelestam M, Frisan T. The Haemophilus ducreyi cytolethal distending toxin activates sensors of DNA damage and repair complexes in proliferating and non-proliferating cells.Cell Microbiol. 2002 Feb;4(2):87-99.
• Sargsyan E, Baryshev M, Szekely L, Sharipo A, Mkrtchian S. Identification of ERp29, an endoplasmic reticulum lumenal protein, as a new member of the thyroglobulin folding complex. J Biol Chem. 2002 May 10;277(19):17009-15. Epub 2002 Mar 07.
• Heessen S, Leonchiks A, Issaeva N, Sharipo A, Selivanova G, Masucci MG, Dantuma NP. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1532-7. Epub 2002 Jan 22.
• Williams NK, Prosselkov P, Liepinsh E, Line I, Sharipo A, Littler DR, Curmi PM, Otting G, Dixon NE. In vivo protein cyclization promoted by a circularly permuted Synechocystis sp. PCC6803 DnaB mini-intein. J Biol Chem. 2002 Mar 8;277(10):7790-8. Epub 2001 Dec 12.
• Liepinsh E, Baryshev M, Sharipo A, Ingelman-Sundberg M, Otting G, MkrtchianS.  Thioredoxin fold as homodimerization module in the putative chaperone ERp29: NMR structures of the domains and experimental model of the 51 kDa dimer. Structure (Camb). 2001 Jun;9(6):457-71.
• Sharipo A, Imreh M, Leonchiks A, Branden C, Masucci MG. cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition. FEBS Lett. 2001 Jun 15;499(1-2):137-42.
• Leonchiks A, Liepinsh E, Barishev M, Sharipo A, Masucci MG, Otting G.  Random coil conformation of a Gly/Ala-rich insert in IkappaB alpha excludes structural stabilization as the mechanism for protection against proteasomal degradation. FEBS Lett. 1998 Dec 4;440(3):365-9.
• Mkrtchian S, Baryshev M, Matvijenko O, Sharipo A, Sandalova T, Schneider G, Ingelman-Sundberg M, Mkrtchian S. Oligomerization properties of ERp29, an endoplasmic reticulum stress protein. FEBS Lett. 1998 Jul 24;431(3):322-6. Erratum in: FEBS Lett 1998 Aug 21;433(3):335.
• Sharipo A, Imreh M, Leonchiks A, Imreh S, Masucci MG. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated IkappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nature Med. 1998 Aug;4(8):939-44.
• Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A,. 1997 Nov 11; 94 (23): 12616-21.
  

Research projects and collaborations

• Gly-Ala repeat of EBV nuclear antigen: influence of ubiquitin-proteasomal degradation: Maria G. Masucci, MTC, Karolinska Institute, Sweden
• ERp29 escort protein of endoplasmic reticulum: Souren Mkrtchian, IMM, Karolinska Institute, Sweden
• Cytochrome P450 2E1: Mechanisms of stability and protein turnover: Magnus Ingelman-Sundberg, IMM, Karolinska Institute, Sweden
• C-ret Drug discovery, 5th framework of EU projects: Carlos Ibanez, Neurology, Karolinska Institute, Sweden
• Proteasomal degradation and wounds in cornea: Per Fagerholm, Linkopping University, Linkopping, Sweden
• Refolding of protein domain structures: Gottfried Otting, University of Australia, Canberra, Australia
• Intein mediated in vitro protein ligation: Nick Dixon, University of Australia, Canberra, Australia
• Mechanisms of HBcAg stability in vivo: Pauls Pumpens, BMC, LU, Riga, Latvia